Prima Biomed (PRR.AX) Revised CAN-004 Trial Of Cvact In Ovarian Cancer Approved In Belgium - First Regulator To Approve Amended CVact Clinical Trial Design
1/20/2014 2:09:33 PM
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, the “Company”) today
announced that the amended CAN-004 protocol was approved by the Belgian Federal Agency for
Medicines and Health Products. This is the first regulatory agency to approve the amended CVac™
clinical trial design. CAN-004 is a multicentre, randomized, phase 2 trial of CVac for the maintenance
treatment of epithelial ovarian cancer in remission.
In November 2013, Prima announced significant updates to its CVacTM clinical development program
based on progression-free survival results from its randomized CAN-003 trial. In the CAN-003 trial, CVac
demonstrated a strong trend of increased progression-free survival in ovarian cancer patients in
remission after second line treatment, as compared to those patients who did not receive CVac.
The CAN-004 trial will enrol a new cohort of 210 epithelial ovarian cancer patients in remission after
second-line platinum-based chemotherapy. 76 patients in remission after first-line surgery and
chemotherapy have previously been randomized onto the CAN-004 trial. Overall survival (OS) will be
the primary endpoint with secondary endpoints including progression-free survival (PFS), adverse
events, and immune monitoring.
Matthew Lehman, Prima’s CEO: “We are very pleased to have received approval for the CAN-004
protocol amendment in Belgium, and we anticipate other regulators will soon follow. It is exciting that
we will soon be able to re-start recruitment of the CVac clinical trial for ovarian cancer.”
Prima maintains updated information about the CAN-004 trial on the U.S. National Institutes of Health
clinical trial registry at www.clinicaltrials.gov and will provide regular updates in the Company’s
quarterly conference calls.
About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic
products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to
bring innovative treatment options to market for patients and to maximize value to shareholders.
Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials.
For further information please contact:
Ms. Jessica Brown, Prima BioMed Ltd.
+1 (919) 710-9061; firstname.lastname@example.org
Mr. James Moses, Mandate Corporate
+61 (0) 420 991 574; email@example.com
Mr. Axel Mühlhaus, edicto GmbH
+49 (0) 69 905505-52; firstname.lastname@example.org
Help employers find you! Check out all the jobs and post your resume.
comments powered by